Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc. (ADIL) Stock Overview
Explore Adial Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
ADIL Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Adial Pharmaceuticals, Inc. (ADIL) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.35.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.83 and a market capitalization of 4.9M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Mr. Cary John Claiborne MBA
5
1180 Seminole Trail, Charlottesville, VA
2018